<DOC>
	<DOCNO>NCT00479024</DOCNO>
	<brief_summary>To determine comparative 1-year outcome renally impaired patient previously underwent cardiac angiography Isovue®-370 Visipaque™ 320 part IOP-104 trial protocol evaluable determination post-contrast significant renal injury ( define &gt; 25 % increase SCr &gt; 25 % increase cystatin C ) .</brief_summary>
	<brief_title>Follow-up Study Previous CARE Trial</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>( previous CARE trial ) • Screening eGFR 20 59 mL/min/1.73m2 Baseline SCr obtain within 72 hour hydration , obtain hydration start , screen blood sample obtain within 72 hour contrast administration At least one post dose blood sample available Received randomize contrast agent Underwent one cardiac angiography procedure ( diagnostic cardiac angiography follow PCI consider one procedure confirm investigator total duration exceed 12 hour ) , study Provides write Informed Consent willing comply protocol requirement ; Was include patient list provide Bracco ; At least 1 year pass since patient 's participation end original CARE trial , determine list provide Bracco • Screening eGFR outside range 20 59 mL/min/1.73m2 Unstable kidney disease require dialysis upon enrollment Prior postdose blood draw , suffer critical clinical event would affect reliability serological measurement renal function Did receive randomize contrast agent per CARE protocol Did undergo cardiac angiography procedure per CARE protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>